Safety Assessment of a Medicinal Probiotic as an Adjunct in Tuberculosis Therapy: Implications for Pharmacy Practice
Pharmacy Practice · 10.08.2026 · 24 (3) · 1-14
DOI: 10.18549/pharmpract.2026.3.3587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Practice, online erschienen am 10.08.2026. Verfasst von Irina Ratnikova und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ratnikova, I., Sadanov, A., Baimakhanova, B., Shorabayev, E., Orazymbet, S., Namaz, E., Turgenbayev, K., Utegenova, N., & Turgumbayeva, A. (2026). Safety Assessment of a Medicinal Probiotic as an Adjunct in Tuberculosis Therapy: Implications for Pharmacy Practice. Pharmacy Practice, 24(3), 1-14. https://doi.org/10.18549/pharmpract.2026.3.3587
Vancouver
Ratnikova I, Sadanov A, Baimakhanova B, Shorabayev E, Orazymbet S, Namaz E, et al. Safety Assessment of a Medicinal Probiotic as an Adjunct in Tuberculosis Therapy: Implications for Pharmacy Practice. Pharmacy Practice. 2026;24(3):1-14. doi:10.18549/pharmpract.2026.3.3587
BibTeX
@article{Ratnikova2026,
author = {Ratnikova, Irina and Sadanov, Amankeldi and Baimakhanova, Baiken and Shorabayev, Erik and Orazymbet, Saltanat and Namaz, Elmira and Turgenbayev, Kairat and Utegenova, Nurshat and Turgumbayeva, Aknur},
title = {Safety Assessment of a Medicinal Probiotic as an Adjunct in Tuberculosis Therapy: Implications for Pharmacy Practice},
journal = {Pharmacy Practice},
year = {2026},
volume = {24},
number = {3},
pages = {1--14},
doi = {10.18549/pharmpract.2026.3.3587}
}
EUVIMED